JP2022534069A5 - - Google Patents
Info
- Publication number
- JP2022534069A5 JP2022534069A5 JP2021569555A JP2021569555A JP2022534069A5 JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5 JP 2021569555 A JP2021569555 A JP 2021569555A JP 2021569555 A JP2021569555 A JP 2021569555A JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910441597 | 2019-05-24 | ||
| CN201910441597.6 | 2019-05-24 | ||
| PCT/CN2020/091606 WO2020238758A1 (zh) | 2019-05-24 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022534069A JP2022534069A (ja) | 2022-07-27 |
| JPWO2020238758A5 JPWO2020238758A5 (https=) | 2023-05-29 |
| JP2022534069A5 true JP2022534069A5 (https=) | 2023-05-29 |
| JP7614650B2 JP7614650B2 (ja) | 2025-01-16 |
Family
ID=73553862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569555A Active JP7614650B2 (ja) | 2019-05-24 | 2020-05-21 | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220315929A1 (https=) |
| EP (1) | EP3992290A4 (https=) |
| JP (1) | JP7614650B2 (https=) |
| CN (1) | CN113891939B (https=) |
| WO (1) | WO2020238758A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| WO2020233680A1 (zh) | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610268B2 (ja) | 2019-05-22 | 2025-01-08 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| AU2020280438B2 (en) * | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP4273245A4 (en) * | 2020-12-29 | 2024-12-11 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| MX2024004011A (es) | 2021-10-01 | 2024-07-01 | Adarx Pharmaceuticals Inc | Composiciones moduladoras de precalicreína y métodos de uso de estas. |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| CN120209051A (zh) * | 2023-12-27 | 2025-06-27 | 武汉人福创新药物研发中心有限公司 | 用于递送的靶向化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| CA2823776A1 (en) * | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| JP6702862B2 (ja) | 2013-07-11 | 2020-06-03 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法 |
| KR102365486B1 (ko) * | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| AU2015209481C1 (en) * | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| EP3862362A3 (en) * | 2014-05-01 | 2021-10-27 | Ionis Pharmaceuticals, Inc. | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| KR102827366B1 (ko) * | 2015-05-06 | 2025-07-03 | 알닐람 파마슈티칼스 인코포레이티드 | 인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법 |
-
2020
- 2020-05-21 US US17/595,576 patent/US20220315929A1/en not_active Abandoned
- 2020-05-21 CN CN202080037247.4A patent/CN113891939B/zh active Active
- 2020-05-21 WO PCT/CN2020/091606 patent/WO2020238758A1/zh not_active Ceased
- 2020-05-21 EP EP20815633.1A patent/EP3992290A4/en not_active Withdrawn
- 2020-05-21 JP JP2021569555A patent/JP7614650B2/ja active Active